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Abstract
Aims Sacubitril/valsartan (SV) reduced heart failure hospitalization and cardiovascular mortality compared with enalapril in
the Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure trial.
However, this trial excluded patients with end stage of renal disease (ESRD); thus, the efficacy and safety of SV in heart failure
with reduced ejection fraction (HFrEF) with ESRD remains uncertain.
Methods and results We retrospectively analysed the clinical and laboratory data of 501 HFrEF patients who administered
with SV from March 2017 to April 2019 in a single tertiary university hospital. A total of 23 HFrEF patients with ESRD on dialysis
[58.3% non-ischaemic heart failure; left ventricular ejection fraction (LVEF): 29.7 ± 4.4%] were included in this study. At base-
line and follow-up visit, we evaluated cardiovascular biomarkers such as high-sensitive troponin T (hsTnT), soluble ST2 (sST2),
echocardiographic parameters, and clinical and adverse events. The mean dose of SV was 90 ± 43 mg/day at baseline and 123
± 62mg/day at last follow-up (follow-up duration: median 132 days). The level of hsTnT was significantly reduced from 236.2 ±
355.3 to 97.0 ± 14.0 pg/mL (P = 0.002), and the sST2 level was significantly reduced from 40.4 ± 44.0 to 19.6 ± 14.1 ng/mL (P =
0.005). LVEF was significantly improved from 29.7 ± 4.4% to 40.8 ± 10.4% (P = 0.002). During the follow-up, up-titration,
down-titration, and maintenance of SV dosing were observed in 7 (30%), 5 (21.7%), and 11 patients (47.8%), respectively.
SV down-titration group had adverse events including symptomatic hypotension (systolic blood pressure <100 mmHg) (n =
4) and dizziness (n = 1), but they did not discontinue SV therapy.
Conclusions We found that SV could safely reduce the hsTnT and sST2 levels and improve LVEF in HFrEF patients with ESRD.
As far as we know, this is the first study to show the efficacy and safety of SV in HFrEF with ESRD on dialysis. Larger prospec-
tive, long-term follow-up study should be warranted.
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Introduction
Sacubitril/valsartan (SV) reduced heart failure (HF) hospitali-
zation and cardiovascular mortality compared with
angiotensin-converting enzyme inhibitor (ACE-I), enalapril in
the Prospective Comparison of ARNI with ACE-I to Determine
Impact on Global Mortality and Morbidity in Heart Failure
(PARADIGM-HF) trial.1 But there are varying levels of evi-
dence for guideline-directed medical therapies for HF in the
chronic kidney disease (CKD) population, with a relative
paucity of data especially in patients with advanced CKD
(Stages 4 and 5) and end stage of renal disease (ESRD).2 Sev-
eral studies in heart failure with reduced ejection fraction
(HFrEF), including PARADIGM-HF trial, suggest that SV can
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slow the decline in kidney function compared with ACE-I/
angiotensin receptor blocker (ARB). However, the
PARADIGM-HF trial excluded patients with advanced CKD
and ESRD, so the efficacy and safety of SV in these population
remains uncertain. There were only two studies for evaluat-
ing SV in advanced CKD patients as far as we know. A
previous study reported that SV could safely decrease blood
pressure (BP) without a decline in kidney function in Japanese
patients with hypertension and renal dysfunction (estimated
glomerular filtration rate, 15 to 60 mL/min/1.73 m2).3 Re-
cently published United Kingdom Heart and Renal
Protection-III (UK HARP-III) trial showed that SV had similar
Table 1 Baseline characteristics, change in clinical parameters, cardiovascular biomarkers, and echocardiographic parameters before and





(N = 14) P-value*
Demographics
Age (years) 67 ± 9 57 ± 20 0.208
Male, n (%) 9 (100) 11 (78.6) 0.266
Duration of heart
failure (years)
5 ± 6 4 ± 5 0.899
Duration of
dialysis (years)
6 ± 4 6 ± 5 0.464
Co-morbidities
Atrial fibrillation, n (%) 1 (11.1) 2 (14.3) 0.825
Hypertension, n (%) 7 (77.8) 11 (78.6) 0.964
Diabetes, n (%) 8 (88.9) 3 (21.4) 0.002
Coronary artery
disease, n (%)
8 (88.9) 3 (21.4) 0.002
Medications
ACE-I or ARB, n (%) 9 (100) 14 (100) >0.999
Beta-blocker, n (%) 9 (100) 14 (100) >0.999
Ivabradine, n (%) 4 (44.4) 13 (92.9) 0.637
Clinical parameters
Systolic BP (mmHg)
Baseline 110 ± 43 109 ± 49 0.727





Baseline 75 ± 23 88 ± 26 0.122





Baseline 73 ± 10 76 ± 10 0.412





High-sensitive troponin T (pg/mL)
Baseline 273.4 ± 421.1 111.5 ± 133.2 0.039




Delta hsTnT (%) 42.2 ± 29.8 13.5 ± 23.4 0.043
sST2 (ng/mL)
Baseline 34.9 ± 4.1 48.4 ± 60.7 0.298




Delta sST2 (%) 47.6 ± 14.7 52.9 ± 23.1 0.569
Echocardiographic parameters
LVEF (%)
Baseline 29.7 ± 2.4 30.5 ± 4.9 0.179




Delta LVEF (%) 22.6 ± 14.4 23.0 ± 22.7 0.911
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; hsTnT, high-sensitive troponin T;
LVEF, left ventricular ejection fraction; sST2, soluble ST2.
*P value for ischaemic vs. non-ischaemic.
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beneficial effects on kidney function and albuminuria to
irbesartan, but it had the additional effect of lowering BP
and cardiac biomarkers [e.g. troponin I and N-terminal pro-
brain natriuretic peptide (NT-proBNP)] in CKD patients (esti-
mated glomerular filtration rate, 20 to 60 mL/min/1.73 m2).4
Methods
We retrospectively analysed the clinical and laboratory data
of 501 HFrEF patients who was prescribed with SV from
March 2017 to April 2019 in a single tertiary university hospi-
tal. We enrolled the following inclusion criteria: age >18
years and left ventricular ejection fraction (LVEF) ≤35% in
echocardiography and anuric ESRD on haemodialysis or peri-
toneal dialysis more than 6months, and we excluded patients
with cardiac resynchronization therapy. Eventually, 23 pa-
tients were included in this study. All patients were switched
from ACE-I/ARB to SV, on top of guideline-directed medical
therapies (beta-blocker 100%, ivabradine 52%). At baseline
and follow-up visit, we evaluated cardiovascular biomarkers
such as high-sensitive troponin T (hsTnT), soluble ST2
(sST2), echocardiographic parameters, and clinical and ad-
verse events.
Results
Mean age was 60 ± 17 years old, and male is 85%. The main
aetiology of HFrEF was non-ischaemic origin cardiomyopathy
(58.3%). The median duration of HF and dialysis was 3 [inter-
quartile range (IQR) 1–8] and 4 (IQR 3–6) years, respectively.
The mean dose of SV was 90 ± 43mg/day at baseline and 123
± 62 mg/day at last follow-up (follow-up duration: median
132, IQR 77–132 days). Table 1 demonstrated the change of
clinical and echocardiographic parameters and biomarkers
before and after SV treatment regarding HF aetiology (ischae-
mic vs. non-ischaemic). From baseline to follow-up, the hsTnT
level was significantly reduced from 236.2 ± 355.3 to 97.0 ±
14.0 pg/mL (P = 0.002, Figure 1A), and the sST2 level was
significantly reduced from 40.4 ± 44.0 to 19.6 ± 14.1 ng/mL
(P = 0.005, Figure 1B). LVEF was significantly improved from
29.7 ± 4.4% to 40.8 ± 10.4% (P = 0.002, Figure 1C), and
diastolic BP was significantly decreased from 76 ± 18 to 69
± 14 mmHg (P = 0.043), but there was no significant differ-
ence in systolic BP (126 ± 16 vs. 121 ± 19 mmHg, P =
0.269). During the follow-up period, up-titration, down-
titration, and maintenance of SV dosing were observed in 7
(30%), 5 (21.7%), and 11 patients (47.8%), respectively. SV
down-titration group had adverse events including symptom-
atic hypotension (systolic BP <100 mmHg) (n = 4) and
dizziness (n = 1), but they did not discontinue SV therapy. In
addition, there were only two cases (10%) of HF hospitaliza-
tion without cardiovascular mortality in our study population.
We analysed the effect of SV in terms of the aetiology of
HF (ischaemic, n = 9 vs. non-ischaemic, n = 14). There was
no significant difference in age, HF, and dialysis duration be-
tween two groups. The hsTnT level was significantly reduced
in both groups. Interestingly, the hsTnT change was signifi-
cantly greater in ischaemic HF than non-ischaemic HF group
(42% vs. 14%, P = 0.043). The sST2 level was significantly
decreased only in non-ischaemic HF group, but the sST2
change was not significantly different between two groups.
In addition, LVEF was significantly improved in both groups,
but the LVEF change was similar between two groups
(22.6% for ischaemic vs. 23.0% for non-ischaemic, P = 0.911).
Figure 1 Change of (A) high-sensitive troponin T, (B) soluble ST2 (sST2),
and (C) left ventricular ejection fraction (LVEF) after sacubitril/valsartan
treatment.
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Aims
However, there have been no studies about SV in ESRD
patients until now. Therefore, we aimed to examine the
effect and safety of SV in the treatment of HFrEF patients
with ESRD.
Conclusions
To our knowledge, this is the first study that shows that SV
could safely reduce the hsTnT and sST2 levels and improve
LVEF in HFrEF patients with ESRD. In ESRD patients, cardiac
biomarkers such as hsTnT and sST2 could be used for risk
stratification.5,6 The hsTnT level has been known to help
identify patients at greater risk of cardiovascular mortality
and sudden cardiac death, and the sST2 level had prognostic
value, independently of renal function and dialysis.7–12 The
UK HARP-III trial showed that SV could decrease troponin T
level compared with olmesartan in advanced CKD patients.4
Recent PIONEER-HF trial also showed that SV could decrease
the hsTnT and sST2 levels more, compared with ACE-I in
acute decompensated HF.13 These lines of recent findings
are consistent with our findings in ESRD patients. In addition,
the clinical implication of more decrease in the hsTnT level
by SV treatment in ischaemic HF group should be confirmed
and evaluated in further studies, although the post hoc
analysis of the PARADIGM-HF trial showed similar adjusted
clinical outcomes across HF aetiology.14 NT-proBNP is a
well-known surrogate marker in HF (especially for HFrEF),
but it can be largely affected by dialysis timing and duration,
so NT-proBNP is not appropriate for evaluating the SV effect
in patients with ESRD.
In terms of safety, most common adverse event related to
SV use was hypotension (systolic BP <100 mmHg), which
occurred during or just after finishing haemodialysis. In our
study, 17% and 4% patients experienced symptomatic hypo-
tension and dizziness, respectively, so we down-titrated their
SV dose. However, this down-titration of SV dose was not re-
lated to stopping SV therapy. Therefore, we suggest that we
could use SV safely in HFrEF patients with ESRD. There have
been only two studies for evaluating SV in advanced CKD
patients but no studies in ESRD patients until now as far as
we know. And two studies for advanced CKD patients were
conducted in hypertensive patients (not HF patients), so our
study may give small but potent clinical evidences for a new
treatment option, SV for the patients with both heart and
kidney failure.
Our study had some limitations. First, our study was not a
randomized controlled trial (RCT) evaluating clinical outcomes
like the PARADIGM-HF trial. Based on our findings, we
suggest RCTs for comparing SV with ACE-I/ARB in terms of
biomarkers, left ventricular reverse remodelling, and clinical
outcomes in HFrEF patients with ESRD. There is an ongoing
observation registry study (ClinicalTrials.gov Identifier:
NCT03771729) that evaluate the clinical role of SV in ad-
vanced CKD patients as far as we know, and further prospec-
tive study regarding clinical outcomes should be warranted to
support the clinical evidence of SV use in patients with
advanced CKD and ESRD. Second, there have been no phar-
macokinetic data of SV in ESRD patients with dialysis although
a pharmacokinetic study using SV showed that renal dysfunc-
tion increased exposure to sacubitrilat (sacubitril metabolite),
not sacubitril (prodrug) in three ESRD patients without dialy-
sis.15 Third, we analysed a small number of patients in Asian
population. However, this is the first study to show the effi-
cacy and safety of SV in HFrEF with ESRD on dialysis. Larger
prospective, long-term follow-up study including RCT should
be warranted.
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